Gujarat Terce Laboratories secured unanimous shareholder approval for all four resolutions at its 41st Annual General Meeting held on August 21, 2026. The voting results confirm the re-appointment of Aalap Prajapati as Managing Director and CEO for a three-year term.

The company issued a corrigendum on the same day to clarify that Prajapati’s tenure is three years, correcting an earlier disclosure that erroneously stated five years. The corrected term runs from October 28, 2026, to October 27, 2029.

Voting Results Overview

Shareholders holding shares as of the cut-off date of August 14, 2026, were eligible to vote. A total of 3,470,935 votes were polled out of 7,791,300 outstanding equity shares, representing a participation rate of 44.55%. All votes cast were in favor of the proposed resolutions, with zero votes against.

The meeting was conducted via video conferencing. Attendance included six promoters and 32 public shareholders. Remote e-voting was conducted between August 18 and August 20, 2026.

Resolution Details

Natwarbhai Prajapati was also re-appointed as a director liable to retire by rotation. The remuneration of M/s. K V M & Co. as Cost Auditors for FY26-27 was ratified.

Leadership Profile

Aalap Prajapati brings over 15 years of experience in the pharmaceutical sector. He holds a management qualification from B.K. School of Business Management, specializing in Marketing and Operations. He is the son of Natwarbhai Prajapati, the company’s Whole-Time Director.

The Board noted Prajapati’s expertise in business strategy, operations management, and marketing. He plays a key role in driving operational efficiency and long-term business development for the firm.

Regulatory Compliance

The disclosure was made pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The earlier corrigendum regarding the tenure correction was filed under Regulation 30(6) read with Schedule III. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

All other particulars in the May 29 intimation remain unchanged. The company has uploaded the revised disclosure and voting results to its website.

Gujarat Terce Laboratories reported a net loss of ₹17.81 lakh for the first quarter ended June 30, 2026 (Q1FY27), widening from a net loss of ₹4.35 lakh in the corresponding period of FY26. The deterioration in profitability was driven by a 17.1% year-on-year decline in revenue from operations to ₹900.24 lakh, which outpaced the reduction in cost of materials consumed. This marks a shift from the profitable trajectory seen in Q4FY26, where the company posted a net profit of ₹10.10 lakh.

The Board of Directors approved the unaudited standalone financial results on August 7, 2026, in compliance with Regulations 30 and 33 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The results were subjected to a limited review by the statutory auditor, Shah Doshi Patel & Associates LLP, who issued an unmodified limited review report. The company operates in the pharmaceutical segment and has prepared its financial statements in accordance with Indian Accounting Standards (Ind AS).

Financial Performance Breakdown

Revenue from operations stood at ₹900.24 lakh in Q1FY27, down from ₹1,085.36 lakh in Q1FY26 and ₹1,139.93 lakh in Q4FY26. Total revenue, including other income of ₹48.23 lakh, amounted to ₹948.47 lakh. Other income saw a significant increase compared to ₹9.48 lakh in the previous year, contributing partially to offsetting operational pressures.

Expenses totaled ₹963.35 lakh, resulting in an operating loss before tax of ₹14.88 lakh. Cost of materials consumed dropped sharply to ₹13.51 lakh from ₹198.38 lakh in Q1FY26, indicating improved input cost management or lower production volumes. However, employee benefit expenses remained high at ₹372.64 lakh, and other expenses were ₹254.39 lakh. Finance costs increased slightly to ₹3.24 lakh from ₹4.93 lakh in the prior year quarter.

What the Numbers Show

The financial data reveals a divergence between cost control and revenue generation. While the company successfully reduced its cost of materials consumed by over 93% year-on-year, this efficiency did not translate into profitability due to a nearly 17% contraction in top-line revenue. The surge in other income to ₹48.23 lakh, up from ₹9.48 lakh in Q1FY26, highlights a growing reliance on non-operational income streams to cushion the bottom line. With employee benefits constituting the largest expense category at ₹372.64 lakh, fixed cost leverage remains a challenge as revenues decline. The widening net loss suggests that current revenue levels are insufficient to cover the company’s fixed operational overheads, despite the sharp reduction in variable material costs.